Phase I/II Study of Z-208 in Advanced Hepatocellular Carcinoma (HCC)

Inclusion criteria:

* Histologically or cytologically confirmed hepatocellular carcinoma
* At least one measurable site of disease according to RECIST criteria that has not been irradiated.
* Child-Pugh classification A \& B
* ECOG performance status of 0-1
* Life expectancy is more than 90 days
* Adequate organ function as defined by the following criteria, Hemoglobin ≥ 8.0 g/dL WBC ≥ 3,000/mm\^3 \<12,000/mm\^3 Absolute neutrophil count ≥ 1,500/mm\^3 Platelet count ≥ 50,000/mm\^3 AST and ALT ≤ 5 times upper limit of normal (ULN) Albumin ≥ 2.8 g/dL Bilirubin ≤ 2.0 mg/dL Creatinine ≤ 1.5 times ULN
* Must provide written informed consent prior to the implementation of any study assessment or procedures

Exclusion criteria

* Patients received treatment with any of the following within the specified timeframe;Any surgical procedure, radiofrequency ablation, intraarterial chemotherapy within 30 days prior to signing the ICF, any treatment with transfusion, albumin preparation, G-CSF within 15 days prior to signing the ICF
* CNS involvement must have completed appropriate treatment
* Prior deep vein thrombosis
* Has ascites, pleural effusions or pericardial fluid refractory
* Active clinically serious infection excluding chronic hepatitis
* Any history of deep vein thrombosis, pulmonary embolism, myocardial infraction, cerebrovascular accident
* Allergy or hypersensitivity to Vitamin A
* Women who are pregnant or breast feeding